Repatha Pediatric Titration Schedule: What Girls and Their Families Need to Know

What Is Repatha and Why Does It Matter for Girls With Familial Hypercholesterolemia?

Repatha (evolocumab) is a fully human monoclonal antibody that inhibits PCSK9, the protein that degrades LDL receptors in the liver. Less PCSK9 means more LDL receptors stay on hepatocyte surfaces, pulling more LDL-cholesterol out of circulation. For girls born with familial hypercholesterolemia (FH), this mechanism addresses the root problem that statins alone often cannot fully correct.

Familial hypercholesterolemia affects approximately 1 in 250 people worldwide, and heterozygous FH (HeFH) is the most common inherited cholesterol disorder a pediatric cardiologist or lipid specialist will see. Girls with HeFH carry LDL levels that typically run 2 to 3 times above normal from birth, and atherosclerosis begins accumulating in childhood. Homozygous FH (HoFH) is rarer, roughly 1 in 160,000 to 1 in 300,000 births, but clinically devastating without aggressive lipid reduction.

The sex-specific dimension matters here. Estrogen provides some cardiovascular protection in the reproductive years, but girls with FH still develop subclinical atherosclerosis earlier than the general population, and that protection evaporates at menopause. Starting effective treatment in childhood changes the lifetime cardiovascular risk curve in a way that no adult intervention fully replicates.

How Evolocumab Works Differently Than a Statin

Statins lower LDL by blocking cholesterol synthesis, which secondarily upregulates LDL receptors. Evolocumab bypasses that pathway entirely: it binds circulating PCSK9 so those receptors are never degraded. In patients with HoFH who have very few functional LDL receptors to begin with, this distinction matters for dose and response expectations.

The Approval History in Pediatric Patients

The FDA extended evolocumab's approval to patients aged 10 and older with HeFH and HoFH in August 2024, based primarily on data from the HAUSER-RCT and the open-label HAUSER-OLE studies. Before that extension, use in children was off-label. Families who started a daughter on evolocumab before 2024 may have been receiving the same dose under a compassionate or off-label framework.

The Pediatric Titration Schedule: Dose Selection, Not Step-Wise Titration

Titration for evolocumab in pediatric patients does not follow the incremental escalation model you see with statins or GLP-1 receptor agonists. There is no "start low, go slow" sequence. The prescribing clinician selects a full therapeutic dose on day one, matched to diagnosis.

HeFH: The Two Dosing Options

For girls aged 10 and older with HeFH, the FDA-approved label specifies:

• 140 mg subcutaneously every 2 weeks, OR
• 420 mg subcutaneously once monthly

Both regimens deliver equivalent annual exposures. The every-two-week schedule may improve adherence for some families because each injection volume is smaller (1 mL vs. 3 sequential 1 mL injections for the 420 mg dose). For a teenage girl who is injection-averse, starting with the 140 mg autoinjector and confirming tolerability before switching to monthly dosing is a clinically reasonable approach, though either is acceptable from the start.

HoFH: Higher Intensity From Day One

For patients with HoFH, the starting dose is 420 mg once monthly. If a girl is already on lipoprotein apheresis, the label supports dosing at 420 mg every two weeks to maintain lipid control between apheresis sessions. Apheresis removes LDL rapidly but transiently; more frequent evolocumab dosing blunts the rebound.

What "Titration" Actually Means in Practice

For evolocumab in pediatric patients, the titration decision tree looks like this:

1. Confirm diagnosis (HeFH vs. HoFH, genetic or clinical criteria).
2. Select dose per indication (140 mg Q2W or 420 mg QM for HeFH; 420 mg QM for HoFH).
3. Check fasting LDL at 4 to 12 weeks after the first injection.
4. If LDL response is inadequate, review adherence and injection technique before attributing failure to the drug. True non-responders with HoFH who lack functional LDL receptors will have blunted response regardless of dose.
5. For HoFH on apheresis, consider escalating to 420 mg Q2W if inter-apheresis LDL rebound is clinically significant.
6. Reassess annually or at major life-stage transitions (menarche, initiation of hormonal contraception, pregnancy planning).

There is no approved dose above 420 mg Q2W in pediatric patients, and no pediatric trial has tested higher doses.

Evidence Base: The HAUSER Trials

The pediatric approval rests on two linked studies. Understanding what they measured, and who they enrolled, helps families set realistic expectations.

HAUSER-RCT: 24-Week Placebo-Controlled Data

The HAUSER-RCT enrolled 157 children aged 10 to 17 with HeFH who were already on background lipid-lowering therapy (mostly statins with or without ezetimibe). Patients were randomized 2:1 to evolocumab 420 mg once monthly or placebo for 24 weeks.

Key results:

| Endpoint | Evolocumab | Placebo | Difference | |---|---|---|---| | Mean LDL-C reduction from baseline | 38.3% | +1.5% | ~40 percentage points | | Patients achieving LDL <130 mg/dL | 54% | 2% |, | | Patients achieving LDL <100 mg/dL | 40% | 0% |, |

Adverse event rates were similar between groups. Injection-site reactions occurred in 4.8% of the evolocumab group vs. 1.9% for placebo, consistent with adult data. No serious cardiovascular events occurred during the trial period, though the study was not powered for hard outcomes.

Roughly half the enrolled patients were female. The trial did not report sex-stratified efficacy data separately, which reflects a persistent gap in pediatric lipid trial design. Women have been historically under-represented in cardiovascular outcome trials, and girls in pediatric trials often receive even less subgroup attention.

HAUSER-OLE: 48-Week Open-Label Extension

The open-label extension followed 141 participants from HAUSER-RCT through 48 additional weeks on active evolocumab. LDL reductions were sustained. Growth, pubertal development, and hormonal markers were monitored and showed no significant differences attributable to evolocumab over 72 total weeks of observation. That safety surveillance is directly relevant for families of young girls, given that puberty coincides with significant hormonal and metabolic shifts.

Sex-Specific Physiology: How Puberty and Hormones Intersect With LDL and Evolocumab

Puberty changes the lipid field in girls in ways that directly affect how you interpret a daughter's cholesterol panel and whether evolocumab response looks as expected.

Estrogen's Effect on LDL

Rising estrogen during puberty upregulates hepatic LDL receptors, which tends to lower LDL modestly in girls during early adolescence. This means a girl's LDL at age 10 may look somewhat lower than it will at age 14, independent of any medication. After menarche, LDL often stabilizes. The practical implication: a lipid panel taken early in puberty may underestimate a girl's lifetime FH burden. Genetic confirmation of FH should drive treatment decisions, not a single LDL reading.

Hormonal Contraception and Lipids

Once a girl becomes sexually active or has a medical indication for hormonal contraception, the contraceptive method can shift her lipid profile. Combined oral contraceptives containing progestins with androgenic activity (like levonorgestrel) can raise LDL and lower HDL. Progestin-only methods and LNG-IUDs have minimal lipid effects. For a girl on evolocumab for FH, the contraceptive choice should be made with her lipid status in mind, and a repeat fasting lipid panel 8 to 12 weeks after starting a new hormonal method is reasonable.

After Menarche: Reassessing the Dosing Schedule

The every-two-weeks versus monthly choice may also intersect with menstrual cycle timing. Some patients prefer to schedule injections on consistent cycle days to help with adherence tracking. There is no pharmacokinetic reason to synchronize injections with the menstrual cycle; the suggestion is purely practical for girls who are building an injection routine.

Pregnancy, Lactation, and Contraception: What Every Menarchal Girl and Her Family Must Know

This section is required reading before prescribing evolocumab to any girl who has reached menarche.

Pregnancy: Evolocumab Is Not Safe

Evolocumab is not approved for use in pregnancy. Animal reproductive studies showed fetal harm at doses producing exposures below the clinical dose. Human data in pregnancy are extremely limited. Because FH itself does not require urgent treatment during a pregnancy that cannot be managed with safer agents, evolocumab should be discontinued before conception is attempted.

The FDA label states that patients who become pregnant while on evolocumab should discontinue the drug and contact their prescriber. This guidance must be communicated to the patient and her family at every prescribing visit, not buried in a handout.

Contraception Requirement

Any menarchal girl on evolocumab who is or may become sexually active should use reliable contraception. The prescriber should document this counseling. Because evolocumab's half-life is approximately 11 to 17 days, drug levels remain detectable for several weeks after the last dose. A washout period of at least 8 weeks before attempted conception is a reasonable precaution based on pharmacokinetic modeling, though no formal guidance specifies an exact interval.

Recommended contraception approaches for adolescents on evolocumab with FH:

• Intrauterine device (hormonal or copper): highly effective, minimal lipid impact with LNG-IUD
• Progestin-only pill: acceptable lipid profile
• Combined oral contraceptive: effective but monitor lipid panel; choose a formulation with low androgenic progestin activity (e.g., desogestrel, norgestimate)
• Barrier methods alone: insufficient reliability for a teratogenic drug context

Lactation

No data exist on evolocumab transfer into human breast milk. IgG antibodies can transfer to breast milk at low levels, and the drug's large molecular weight (approximately 144 kDa) limits gut absorption by a breastfeeding infant. Given the lack of human lactation data and the non-urgent nature of lipid therapy in the postpartum period, discontinuing evolocumab while breastfeeding and resuming after weaning is the conservative standard. Families should discuss this transition timeline with their lipid specialist before delivery.

Who This Is Right For and Who Should Wait

Girls Who Are Good Candidates for Evolocumab

• Age 10 or older with confirmed or clinically diagnosed HeFH who have not reached LDL goal (<130 mg/dL, or <100 mg/dL with additional risk factors) on maximally tolerated statin therapy with or without ezetimibe
• Any age-eligible patient with HoFH
• Girls with statin intolerance (myopathy, transaminase elevation) who need an alternative lipid-lowering strategy
• Patients whose families prefer an injection every 2 weeks or monthly over daily oral medication

Girls Who Should Wait or Use Caution

• Girls under age 10: not approved, insufficient safety data
• Any patient who is pregnant or planning pregnancy in the near term
• Patients whose LDL is at goal on current therapy: adding evolocumab without a clear residual risk rationale is not indicated
• Families without the capacity for safe injection administration at home or who lack access to refrigeration for the drug (Repatha must be kept at 2 to 8 degrees Celsius)

A Note on Girls With PCOS

Polycystic ovary syndrome (PCOS) is associated with insulin resistance, dyslipidemia, and an atherogenic lipid profile (elevated triglycerides, low HDL, small dense LDL). PCOS is not a direct indication for evolocumab, but a teenage girl with both PCOS and FH carries compounded cardiovascular risk. If she is being managed for FH with evolocumab, her PCOS-related metabolic markers should be tracked in parallel. The Androgen Excess and PCOS Society recommends cardiovascular risk stratification in all adolescents with PCOS.

Injection Technique and Administration for Pediatric Patients

Getting the injection technique right is especially important for children and teenagers, who may be administering the drug themselves or with parental assistance.

Device Options

• SureClick autoinjector (140 mg/mL): spring-loaded, requires no manual plunger depression; preferred for many adolescents
• Prefilled syringe (140 mg/mL): requires manual injection; some patients find this easier to control
• Pushtronex device (420 mg): worn on-body for 9 minutes; delivers the full monthly dose without three separate injections; may improve acceptability for monthly dosing

Site Selection and Rotation

Recommended injection sites: abdomen (avoid a 2-inch radius around the navel), outer thigh, and upper arm (with assistance). Rotate sites with each injection. Injection-site reactions occurred in approximately 4.8% of pediatric patients in HAUSER-RCT; most were mild erythema or bruising that resolved without intervention.

Refrigerated Repatha should be allowed to reach room temperature for at least 30 minutes before injection to reduce discomfort.

Storage

Store at 2 to 8 degrees Celsius (36 to 46 degrees Fahrenheit) in the original carton. Do not freeze. If removed from the refrigerator, the drug may be stored at room temperature (up to 25 degrees Celsius) for up to 30 days.

Monitoring Schedule After Initiating Evolocumab

Lipid Panel Timing

Check a fasting lipid panel 4 to 12 weeks after the first injection to confirm LDL response. After that, a standard monitoring interval for stable patients on PCSK9 inhibitor therapy is every 6 to 12 months, or sooner if a medication change occurs.

Safety Labs

Evolocumab does not require routine hepatic or renal function monitoring on the same schedule as statins. The HAUSER-OLE data showed no evolocumab-attributable signal in liver enzymes, creatine kinase, or growth markers over 72 weeks. Still, any patient who develops unexplained muscle pain, weakness, or transaminase elevation should be evaluated, particularly if a background statin is still in use.

Pubertal and Growth Monitoring

Because HAUSER-OLE tracked pubertal development explicitly, clinicians can reassure families that available data through 72 weeks showed no interference with normal pubertal progression. Growth velocity and Tanner staging did not differ significantly between evolocumab-treated and historical comparators. Longer-term data beyond 72 weeks in this age group are still accumulating.

Cost, Access, and Insurance Navigation for Families

Evolocumab carries a list price that exceeds most families' out-of-pocket capacity. Amgen's Repatha Copay Card and patient assistance program can reduce costs substantially for commercially insured or uninsured patients. For pediatric patients with a confirmed FH diagnosis and documented statin therapy, prior authorization is typically granted by major insurers, though documentation requirements vary by plan.

The National Lipid Association's FH Foundation maintains a registry and assistance navigation service that families of children with HeFH or HoFH may find useful, though the primary sources for dosing decisions remain the FDA label and the treating lipid specialist.

Communicating With Your Daughter's Care Team

A teenage girl should be included in discussions about her own treatment, not just her parents. Developmentally appropriate conversations about why her cholesterol is different, what evolocumab does, and what the injection schedule will look like can improve long-term adherence. Adolescent adherence to chronic disease regimens improves significantly when the adolescent is treated as a participant in decision-making rather than a passive recipient.

Specific things to address at each visit with the patient directly:

• Where she is storing and refrigerating the drug
• Whether she is administering injections herself or with help
• Any injection-site reactions or concerns
• Menstrual cycle history and sexual activity status (for contraception counseling)
• Whether she has questions about long-term use